Fen Phen Lawsuit Loans

Fen-Phen Lawsuit Funding

TriMark Legal Funding LLC provides fast, affordable lawsuit post-settlement funding cash advances from $1,000 up to $25,000 – often in as little as 48 hours for plaintiffs with settled Fen Phen lawsuits. We also offer lawsuit loans for defective drug lawsuits, defective medical devices, and many other types of multidistrict litigation and personal injury cases.

Fen Phen Side Effects: Primary Pulmonary Hypertension

Fen-Phen, a diet drug marketed as Redux, Fenfluramine, Dexfenfluramine, and Pondimin, had been considered safe for many years until the FDA requested its removal from store shelves in 1997. Rising reports of heart valve disease caused the FDA to take the action against Fen-Phen, particularly after echocardiograms of women who had ingested the drug indicated a 30% rate of heart valve abnormality, even though no other symptoms had been reported.

atients suffering from Primary Pulmonary Hypertension (PPH) caused by Fen-Phen are NOT involved in the Nationwide Class Action Settlement Agreement with American Home Products. PPH patients must file independent lawsuits to make legal claims. TriMark Legal Funding LLC funds on both the Fen-Phen class action suit and independent PPH lawsuits.

What is Fen-Phen?

Fen-Phen (also marketed under the names Phen-Fen, Pondimin and Redux) is an anti-obesity medication consisting of two drugs: fenfluramine and phentermine. Fenfluramine, and later, a related drug, dexfenfluramine, was marketed by Wyeth, now known as American Home Products.

Fen-Phen Maker Agrees to $3.75 Billion Settlement

American Home Products Corporation (AHP), makers of the diet drug combination Fen-Phen, agreed Thursday to pay $3.75 billion in compensation to thousands of people who used the diet drugs and developed Primary Pulmonary Hypertension (PPH) before they were removed from the market in 1997 after being linked to heart valve disease.

After reports of valvular heart disease and pulmonary hypertension, primarily in women who had been undergoing treatment with Fen-Phen, the Food and Drug Administration (FDA) requested its withdrawal from the market in September 1997.

Fen-Phen decreased hunger by increasing Seratonin levels in the brain, which then caused the user to have feelings of fullness or satiety. Fenfluramine (Fen) the first ingredient in the drug, when used alone was shown to cause severe mood swings and depression. So, phentermine (Phen) was added to Fen, because it effectively counterbalanced depression, and the two drugs working as one were able to stave off hunger, without any of the resultant emotional problems.

But, it was found that the combination of these two ingredients in Fen-Phen was not safe, and severe health consequences resulted from patient usage, despite Fen Phen lawyers arguing there was no connection.

As a result of these findings, Fen-Phen class-action lawsuits have grown to over 500,000 since April 2005, according to American Lawyer magazine, and Fen-Phen lawyers should only anticipate more filings to come.

Cases of Fen-Phen and SSRI-Related Lung Disorder Rise